Targeted protein degradation to attenuate adoptive T-cell therapy associated adverse inflammatory responses
US11046954B2 · kind B2 · utility
0Cited by
10References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 6, 2018 |
| Grant date | Jun 29, 2021 |
| Priority date | — |
| Expiry date | Feb 6, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2800/80
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention is in the area of compositions and methods for regulating chimeric antigen receptor immune effector cell, for example T-cell (CAR-T), therapy to modulate associated adverse inflammatory responses, for example, cytokine release syndrome and tumor lysis syndrome, using targeted protein degradation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.